Detalhe da pesquisa
1.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Health Qual Life Outcomes
; 17(1): 173, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729982
2.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 18(3): 297-311, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28139405